perspectives on immunomodulators and biologics: risk of neoplasia and malignancy development
Published 7 years ago • 218 plays • Length 18:02Download video MP4
Download video MP3
Similar videos
-
21:04
risks of malignancies due to ibd and immunomodulators and/or biologic therapy
-
19:03
debate: ibd patient on biologic or immunomodulator who develops a malignancy - may continue meds
-
24:47
diagnosis and management of infections in ibd patients on immunomodulators and biologics
-
11:32
debate: ibd patient on biologic or immunomodulator who develops a malignancy - must stop these meds
-
21:14
when and how to use immunomodulators and biologics in ibd
-
19:37
how often do immunomodulators and/or biologics cause lymphoma and/or cancer, and can we prevent it?
-
18:39
what are the skin side effects due to immunomodulators and/or biologics?
-
45:53
improvements in targeted ibd management: innovative biologics and small molecules
-
23:44
mechanisms of disease: biologic pipeline for ibd
-
21:09
infections due to immunomodulators and/or biologics: identification, prevention and treatment
-
18:22
other major side effects due to immunomodulators and/or biologics in our ibd patients
-
18:43
neurologic, rheumatologic, and optic complications related to immunomodulators and biologic
-
12:58
positioning of biologics and new therapeutics for crohn's disease
-
12:12
debate: immunomodulators and anti-tnfs must be stopped when an infection occurs
-
18:23
who should receive early anti-tnf therapy: with what benefits and risks?
-
21:02
should we change how we position biologics for use in crohn’s disease?
-
11:40
debate: biosimilar therapies - caution, more studies are needed
-
49:17
the evolving therapeutic paradigm in ibd: optimal positioning of new and emerging agents
-
17:20
b-cell maturation antigen: a new biomarker for b-cell malignancies